Key result
PDGF-BB stimulates mesangial-cell hyperplasia with sustained MAP kinase activation, whereas angiotensin II causes hypertrophy with transient MAP kinase activation.
The differing potency and duration of MAP kinase activation by PDGF-BB and angiotensin II may explain their distinct effects on mesangial cell hyperplasia versus hypertrophy.
Answers are grounded in this paper and cite their sources.
Differential MAP kinase signaling may drive mesangial phenotypes in kidney disease; hypothesis-generating for targeted human therapies.
Exposure of mesangial cells to platelet-derived growth factor (PDGF) BB caused a significant stimulation of cell proliferation and protein synthesis, as measured by [3H]thymidine incorporation and [3H]leucine incorporation respectively. In contrast, cells treated with angiotensin II had no significant increase in [3H]thymidine incorporation, but demonstrated a marked increase in [3H]leucine incorporation. Furthermore, angiotensin II significantly increased total protein content per cell. These data show that, whereas PDGF-BB is a mitogen and stimulates mesangial-cell hyperplasia, angiotensin II causes hypertrophy of the cells without hyperplasia. Treatment of mesangial cells with PDGF and angiotensin II rapidly and dose-dependently stimulated mitogen-activated protein (MAP) kinase activity, as shown by an assay for activity in vitro using myelin basic protein as a substrate, and by immunoprecipitation of 32P-labelled cells with specific antibodies against the 42 kDa and 44 kDa mitogen-activated protein kinases p42mapk and p44mapk, respectively. Whereas stimulation with PDGF-BB caused a potent and sustained (for more than 30 min) phosphorylation and activation of p42mapk and p44mapk, as well as of the upstream activators MAP kinase kinase and c-Raf, the effect of angiotensin II was less potent, reaching a peak at 5-10 min and thereafter declining rapidly. In summary, these results suggest that PDGF-BB and angiotensin II differ in their potency and duration of activation of the MAP kinase cascade, which may explain why PDGF-BB is a potent mitogen for mesangial cells, whereas angiotensin II only triggers mesangial-cell hypertrophy.
No takes yet. Share an insight, caveat, or question.
Huwiler et al. (1995) studied this question. Platelet-derived growth factor (PDGF) BB and angiotensin II was evaluated on MAP kinase activity, cell proliferation, and protein synthesis. PDGF-BB stimulates mesangial-cell hyperplasia with sustained MAP kinase activation, whereas angiotensin II causes hypertrophy with transient MAP kinase activation.
Synapse has enriched 10 related papers. Consider them for comparative context: